Ventyx Biosciences, Inc. (VTYX)
NASDAQ: VTYX · Real-Time Price · USD
13.95
-0.01 (-0.07%)
At close: Feb 3, 2026, 4:00 PM EST
13.99
+0.04 (0.29%)
After-hours: Feb 3, 2026, 7:55 PM EST
Ventyx Biosciences Employees
Ventyx Biosciences had 83 employees as of September 30, 2025. The number of employees increased by 8 or 10.67% compared to the same quarter last year.
Employees
83
Change
8
Growth
10.67%
Revenue / Employee
n/a
Profits / Employee
-$1,284,422
Market Cap
1.00B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 83 | 8 | 10.67% | 83 | 0 |
| Jun 30, 2025 | 81 | 8 | 10.96% | 81 | 0 |
| Mar 31, 2025 | 81 | 7 | 9.46% | 81 | 0 |
| Dec 31, 2024 | 82 | 2 | 2.50% | 79 | 3 |
| Sep 30, 2024 | 75 | -24 | -24.24% | 75 | 0 |
| Jun 30, 2024 | 73 | -18 | -19.78% | 73 | 0 |
| Mar 31, 2024 | 74 | -2 | -2.63% | 74 | 0 |
| Dec 31, 2023 | 80 | 21 | 35.59% | 79 | 1 |
| Sep 30, 2023 | 99 | 55 | 125.00% | 99 | 0 |
| Jun 30, 2023 | 91 | 57 | 167.65% | 91 | 0 |
| Mar 31, 2023 | 76 | 45 | 145.16% | 76 | 0 |
| Dec 31, 2022 | 59 | 32 | 118.52% | 58 | 1 |
| Sep 30, 2022 | 44 | 21 | 91.30% | 44 | 0 |
| Jun 30, 2022 | 34 | 11 | 47.83% | 34 | 0 |
| Mar 31, 2022 | 31 | - | - | 31 | 0 |
| Dec 31, 2021 | 27 | - | - | 27 | 0 |
| Sep 30, 2021 | 23 | - | - | 23 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| Vir Biotechnology | 408 |
| ARS Pharmaceuticals | 167 |
| CytomX Therapeutics | 121 |
| ORIC Pharmaceuticals | 106 |
| Nanobiotix | 103 |
| Theravance Biopharma | 97 |
| GH Research | 50 |
VTYX News
- 13 days ago - Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 26 days ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX) - Newsfile Corp
- 27 days ago - Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal - Reuters
- 27 days ago - Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - PRNewsWire
- 4 weeks ago - Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports - Reuters
- 4 weeks ago - Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter - WSJ
- 2 months ago - Ventyx Provides Clinical and Corporate Updates - GlobeNewsWire
- 2 months ago - Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire